Srini Mukundan is Reveal's Medical Director, currently overseeing Phase 2 clinical studies for the first gadolinium-free general purpose MRI contrast agent, RVP-001. Prior to joining Reveal, Srini was Chief of Magnetic Resonance Imaging (MRI), Chief of Neuroradiology, Chair of the Contrast Agent Safety Committee, and Director of MRI Innovation and Strategy at Brigham and Women’s Hospital, and Associate Professor in Radiology at Harvard Medical School. In these roles Srini championed innovation and clinical translation: developing advanced techniques and clinical programs for imaging of brain tumors and of multiple sclerosis; introducing advanced imaging resources and leading the selection of new contrast agents. Srini directed MRI operations across all BrighamHealth sites, overseeing over 100,000 MRIs per year. Srini has a PhD in bioinorganic chemistry and an MD from Emory University, where he completed all his training.